The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs Gastroenterology

BMC Research Notes

Volumn 9, Issue 1, 2016, Pages

  Wewer Albrechtsen, Nicolai J ^a   Kuhre, Rune E ^a   Toräng, Signe ^a   Holst, Jens J ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Distribution of gut hormones in the mouse rat and pig; Gastrointestinal tract; Gut hormones

Indexed keywords

GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 2; GLUCOSE; NEUROTENSIN; OXYNTOMODULIN; PEPTIDE; PEPTIDE YY;

ANIMAL; APPETITE; C57BL MOUSE; INTESTINE; MALE; METABOLISM; PIG; WISTAR RAT;

ANIMALS; APPETITE; GLUCAGON-LIKE PEPTIDE 1; GLUCAGON-LIKE PEPTIDE 2; GLUCOSE; INTESTINES; MALE; MICE, INBRED C57BL; NEUROTENSIN; OXYNTOMODULIN; PEPTIDE YY; PEPTIDES; RATS, WISTAR; SUS SCROFA;

EID: 84956870345     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/s13104-016-1872-2     Document Type: Article

References (42)

1. Chaudhri OB, Salem V, Murphy KG, Bloom SR. Gastrointestinal satiety signals. Annu Rev Physiol. 2008;70:239-55.
2. Field BC, Chaudhri OB, Bloom SR. Bowels control brain: gut hormones and obesity. Nat Rev Endocrinol. 2010;6(8):444-53. doi: 10.1038/nrendo.2010.93.
3. Holst JJ. Incretin hormones and the satiation signal. Int J Obes (2005). 2013;37(9):1161-8. doi: 10.1038/ijo.2012.208.
4. Heer J, Rasmussen C, Coy DH, Holst JJ. Glucagon-like peptide-1, but not glucose-dependent insulinotropic peptide, inhibits glucagon secretion via somatostatin (receptor subtype 2) in the perfused rat pancreas. Diabetologia. Springer-Verlag; 2008. p. 2263-70.
5. Svendsen B, Pedersen J, Albrechtsen NJW, Hartmann B, Toräng S, Rehfeld JF, et al. An analysis of cosecretion and coexpression of gut hormones from male rat proximal and distal small intestine. Endocrinology. 2015;156(3):847-57. doi: 10.1210/en.2014-1710.
6. Bordeaux J, Welsh AW, Agarwal S, Killiam E, Baquero MT, Hanna JA, et al. Antibody validation. Biotechniques. 2010;48(3):197-209. doi: 10.2144/000113382.
7. Burry RW. Specificity controls for immunocytochemical methods. J Histochem Cytochem. 2000;48(2):163-5. doi: 10.1177/002215540004800201.
8. Kurien B, Dorri Y, Dillon S, Dsouza A, Scofield RH. An overview of western blotting for determining antibody specificities for immunohistochemistry. In: Kalyuzhny AE, editor. Signal transduction immunohistochemistry. methods in molecular biology. New York: Humana Press; 2011. p. 55-67.
9. Berglund L, Björling E, Oksvold P, Fagerberg L, Asplund A, Al-Khalili Szigyarto C, et al. A genecentric human protein atlas for expression profiles based on antibodies. Mol Cell Proteomics. 2008;7(10):2019-27. doi: 10.1074/mcp.R800013-MCP200.
10. Ha M, Kim VN. Regulation of microRNA biogenesis. Nat Rev Mol Cell Biol. 2014;15(8):509-24. doi: 10.1038/nrm3838.
11. Day D, Tuite M. Post-transcriptional gene regulatory mechanisms in eukaryotes: an overview. J Endocrinol. 1998;157(3):361-71. doi: 10.1677/joe.0.1570361.
12. King AJF. The use of animal models in diabetes research. Br J Pharmacol. 2012;166(3):877-94. doi: 10.1111/j.1476-5381.2012.01911.x.
13. van der Wielen N, van Avesaat M, de Wit NJW, Vogels JTWE, Troost F, Masclee A, et al. Cross-species comparison of genes related to nutrient sensing mechanisms expressed along the intestine. PLoS One. 2014;9(9):e107531. doi: 10.1371/journal.pone.0107531.
14. Wewer Albrechtsen NJ, Hornburg D, Torang S, Kuhre RE, Deacon CF, Meissner F et al. A novel immune-based approach for measurement of the anorectic gut hormone oxyntomodulin: changes after gastric bypass surgery. Diabetes. 2015;2076-P(supplementary).
15. Bak MJ, Albrechtsen NW, Pedersen J, Hartmann B, Christensen M, Vilsbøll T, et al. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur J Endocrinol. 2014;170(4):529-38. doi: 10.1530/eje-13-0941.
16. Bak MJ, Wewer Albrechtsen NJ, Pedersen J, Knop FK, Vilsboll T, Jorgensen NB, et al. Specificity and sensitivity of commercially available assays for glucagon-like peptide-1 (GLP-1): implications for GLP-1 measurements in clinical studies. Diab Obes Metab. 2014;16(11):1155-64. doi: 10.1111/dom.12352.
17. Kuhre RE, Albrechtsen NJW, Hartmann B, Deacon CF, Holst JJ. Measurement of the incretin hormones: glucagon-like peptide-1 and glucose-dependent insulinotropic peptide. J Diab Complicat. 2014. doi: 10.1016/j.jdiacomp.2014.12.006.
18. Orskov C, Rabenhoj L, Wettergren A, Kofod H, Holst JJ. Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans. Diabetes. 1994;43(4):535-9.
19. Kuhre RE, Bechmann LE, Wewer Albrechtsen NJ, Hartmann B, Holst JJ. Glucose stimulates neurotensin secretion from the rat small intestine by mechanisms involving SGLT1 and GLUT2 leading to cell depolarization and calcium influx. Am J physiol Endocrinol Metab. 2015. doi: 10.1152/ajpendo.00012.2015 (ajpendo.00012.2015).
20. Kuhre RE, Albrechtsen NW, Windelov JA, Svendsen B, Hartmann B, Holst JJ. GLP-1 amidation efficiency along the length of the intestine in mice, rats and pigs and in GLP-1 secreting cell lines. Peptides. 2014;55:52-7. doi: 10.1016/j.peptides.2014.01.020.
21. Wewer Albrechtsen NJ, Bak MJ, Hartmann B, Christensen LW, Kuhre RE, Deacon C, et al. Stability of glucagon-like peptide-1 and glucagon in human plasma. Endocr Connect. 2015. doi: 10.1530/ec-14-0126.
22. Hartmann B, Thulesen J, Kissow H, Thulesen S, Orskov C, Ropke C, et al. Dipeptidyl peptidase IV inhibition enhances the intestinotrophic effect of glucagon-like peptide-2 in rats and mice. Endocrinology. 2000;141(11):4013-20.
23. Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R, et al. Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and man. EurJ Clin Invest. 1992;22(4):283-91.
24. Adrian TE, Bacarese-Hamilton AJ, Smith HA, Chohan P, Manolas KJ, Bloom SR. Distribution and postprandial release of porcine peptide YY. J Endocrinol. 1987;113(1):11-4.
25. Cho H-J, Kosari S, Hunne B, Callaghan B, Rivera L, Bravo D, et al. Differences in hormone localisation patterns of K and L type enteroendocrine cells in the mouse and pig small intestine and colon. Cell Tissue Res. 2015;359(2):693-8. doi: 10.1007/s00441-014-2033-3.
26. Miyachi Y, Jitsuishi W, Miyoshi A, Fujita S, Mizuchi A, Tatemoto K. The distribution of polypeptide YY-like immunoreactivity in rat tissues. Endocrinology. 1986;118(6):2163-7. doi: 10.1210/endo-118-6-2163.
27. Roddy DR, Koch TR, Reilly WM, Carney JA, Go VL. Identification and distribution of immunoreactive peptide YY in the human, canine, and murine gastrointestinal tracts: species-related antibody recognition differences. Regul Pept. 1987;18(3-4):201-12.
28. Zhou J, Hegsted M, McCutcheon KL, Keenan MJ, Xi X, Raggio AM, et al. Peptide YY and proglucagon mRNA expression patterns and regulation in the gut. Obesity. 2006;14(4):683-9. doi: 10.1038/oby.2006.77.
29. Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM, Bloom SR. Human distribution and release of a putative new gut hormone, peptide YY. Gastroenterology. 1985;89(5):1070-7.
30. Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409-39. doi: 10.1152/physrev.00034.2006.
31. Orskov C, Holst JJ, Knuhtsen S, Baldissera FG, Poulsen SS, Nielsen OV. Glucagon-like peptides GLP-1 and GLP-2, predicted products of the glucagon gene, are secreted separately from pig small intestine but not pancreas. Endocrinology. 1986;119(4):1467-75.
32. Mortensen K, Christensen LL, Holst JJ, Orskov C. GLP-1 and GIP are colocalized in a SUBSET of endocrine cells in the small intestine. Regul Pept. 2003;114(2ΓÇô3):189-96.
33. Larsson LI, Holst J, Hakanson R, Sundler F. Distribution and properties of glucagon immunoreactivity in the digestive tract of various mammals: an immunohistochemical and immunochemical study. Histochemistry. 1975;44(4):281-90.
34. Evers BM, Rajaraman S, Chung DH, Townsend CM, Wang X, Graves K, et al. Differential expression of the neurotensin gene in the developing rat and human gastrointestinal tract. Am J Physiol Gastrointest Liver Physiol. 1993;265(3):G482-90.
35. Bryant MG, Bloom SR. Distribution of the gut hormones in the primate intestinal tract. Gut. 1979;20(8):653-9.
36. Habib AM, Richards P, Cairns LS, Rogers GJ, Bannon CAM, Parker HE, et al. Overlap of endocrine hormone expression in the mouse intestine revealed by transcriptional profiling and flow cytometry. Endocrinology. 2012;153(7):3054-65. doi: 10.1210/en.2011-2170.
37. Böttcher G, Sjölund K, Ekblad E, Håkanson R, Schwartz TW, Sundler F. Coexistence of peptide YY and glicentin immunoreactivity in endocrine cells of the gut. Regul Pept. 1984;8(4):261-6. doi: 10.1016/0167-0115(84)90034-X.
38. Kissow H, Hartmann B, Holst JJ, Poulsen SS. Glucagon-like peptide-1 as a treatment for chemotherapy-induced mucositis. Gut. 2012. doi: 10.1136/gutjnl-2012-303280.
39. Roberge JN, Brubaker PL. Regulation of intestinal proglucagon-derived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology. 1993;133(1):233-40. doi: 10.1210/endo.133.1.8319572.
40. Hansen L, Holst JJ. The effects of duodenal peptides on glucagon-like peptide-1 secretion from the ileum: a duodeno-ileal loop? Regul Pept. 2002;110(1):39-45. doi: 10.1016/S0167-0115(02)00157-X.
41. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Investig. 1993;91(1):301-7. doi: 10.1172/JCI116186.
42. Wood S. Distribution of gut peptides and their actions. In: Bennett A, Velo G, editors. Mechanisms of gastrointestinal motility and secretion. NATO ASI series. US: Springer; 1984. p. 109-16.